Clinical Trial

HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Thie purpose of this study is to find out whether a personalized treatment approach-using a series of ctDNA tests along with standard imaging scans to help decide when to step up (escalate) or decrease (de-escalate) sequential treatments (given one after another)-combined with local therapies (which treat cancer in a specific part of the body) and treatments that prevent cancer from spreading to the central nervous system (CNS; including the brain and spinal cord) can result in long-lasting remission and possibly cure some participants with HER2+ metastatic breast cancer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-03-05; most recent amendment 2026-05-20.
Trial Details
NCT Number NCT07459673
Lead Sponsor Memorial Sloan Kettering Cancer Center
Conditions Breast Cancer, HER2-positive Breast Cancer, Breast Cancer Stage IV
Enrollment 60 participants
Start Date 2026-03-04
Primary Completion 2030-03-04 (estimated)
Study Completion 2030-03-04 (estimated)
Updated on ClinicalTrials.gov 2026-05-22